Compugen (NASDAQ:CGEN – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
Separately, Truist Financial lowered their target price on shares of Compugen from $5.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, May 21st.
Compugen Price Performance
Shares of CGEN remained flat at $2.03 during trading hours on Tuesday. The stock had a trading volume of 103,930 shares, compared to its average volume of 559,089. The firm has a fifty day simple moving average of $2.13 and a two-hundred day simple moving average of $2.03. The stock has a market capitalization of $175.84 million, a price-to-earnings ratio of -10.68 and a beta of 2.71. Compugen has a twelve month low of $0.53 and a twelve month high of $3.03.
Institutional Investors Weigh In On Compugen
Hedge funds have recently bought and sold shares of the company. Heron Bay Capital Management bought a new stake in Compugen during the 1st quarter worth approximately $32,000. Tocqueville Asset Management L.P. acquired a new stake in shares of Compugen during the third quarter worth $71,000. Finally, Silverarc Capital Management LLC lifted its position in Compugen by 6.1% in the 3rd quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 20,000 shares in the last quarter. 12.22% of the stock is currently owned by institutional investors and hedge funds.
Compugen Company Profile
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.